S
Seung-Mo Hong
Researcher at University of Ulsan
Publications - 383
Citations - 21628
Seung-Mo Hong is an academic researcher from University of Ulsan. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 53, co-authored 361 publications receiving 17907 citations. Previous affiliations of Seung-Mo Hong include University of Virginia Health System & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma
Olca Basturk,Michael F. Berger,Hiroshi Yamaguchi,Volkan Adsay,Gokce Askan,Umesh Bhanot,Ahmet Zehir,Fátima Carneiro,Seung-Mo Hong,Giuseppe Zamboni,Esra Dikoglu,Vaidehi Jobanputra,Kazimierz O. Wrzeszczynski,Serdar Balci,Peter J. Allen,Naoki Ikari,Shoko Takeuchi,Hiroyuki Akagawa,Atsushi Kanno,Tooru Shimosegawa,Takanori Morikawa,Fuyuhiko Motoi,Michiaki Unno,Ryota Higuchi,Masakazu Yamamoto,Kyoko Shimizu,Toru Furukawa,David S. Klimstra +27 more
TL;DR: The results suggest that intraductal tubulopapillary neoplasm has distinguishing genetic characteristics and some of these mutated genes are potentially targetable.
Journal ArticleDOI
Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors
TL;DR: Pancreatic cancers with low DNMT1 expression tend to be more sensitive to low-dose 5-azadeoxycytidine, and loss ofDNMT1 alleles may reduce DN MT1 levels in some pancreatic cancers.
Journal ArticleDOI
Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations.
Yong Soon Chun,Yong Soon Chun,Savita Bisht,Venugopal Chenna,Dipankar Pramanik,Takahiro Yoshida,Seung-Mo Hong,Roeland F. de Wilde,Zhe Zhang,David L. Huso,Ming Zhao,Michelle A. Rudek,Vered Stearns,Anirban Maitra,Saraswati Sukumar +14 more
TL;DR: The potential for i.duc NanoCurc as an alternative to the oral route for breast cancer chemoprevention in high-risk cohorts is confirmed and reduction in cancer incidence was associated with significant decrease in nuclear factor -κB activation in the nanoCurc treated mammary epithelium explants, compared to either control or oral curcumin- administered rats.
Journal ArticleDOI
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response.
Junho Kang,Jae Ho Jeong,Hee-Sang Hwang,Sang Soo Lee,Do Hyun Park,Dongwook Oh,Tae Jun Song,Ki-Hun Kim,Shin Hwang,Dae Wook Hwang,Song Cheol Kim,Jin-Hong Park,Seung-Mo Hong,Kyu-Pyo Kim,Baek-Yeol Ryoo,Changhoon Yoo +15 more
TL;DR: Pembrolizumab showed modest anti-tumor activity in heavily pretreated PD-L1–positive BTC patients and in patients who showed objective response, durable response could be achieved.
Journal ArticleDOI
Analysis of extrahepatic bile duct carcinomas according to the New American Joint Committee on Cancer staging system focused on tumor classification problems in 222 patients
TL;DR: Although the sixth edition of the American Joint Committee on Cancer (AJCC) staging system for extrahepatic bile duct carcinoma was updated, the system has a problem on T classification due to its ambiguous definition of T1 as “tumor confined to biliary duct histologically” and T2 as ”tumors invading beyond the bileduct.